Medtronic Japan Co., Ltd.
Tokyo, 1080075, Japan
NCT Number: NCT07091916
The study is designed to characterize the acute safety and performance of the EV ICD System for Japanese patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Tokyo, 1080075, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
[i] Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias. [ii] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal 2015 36:41 (2793-2867). https://doi.org/10.1093/eurheartj/ehv316
Exclusion criteria
Or any other prior/planned medical intervention not listed that precludes their participation in the opinion of the Investigator.
[iii] 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing). [iv] ACC/AHA/HRS guidelines for Cardiac Resynchronization Therapy. [v] As documented on echo or MRI. [vi] As documented on CT scan or MRI.
VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
Time frame: 2 weeks (14 days) post-implant
The endpoint is defined as a subject's first occurrence of a major complication related to the EV ICD System and/or procedure, as determined by an independent Clinical Events Committee (CEC), that occurs on or prior to 2 weeks (14 days) post-implant.
Time frame: At Implant
Each subject will demonstrate a successful defibrillation outcome if either 2 successive induced ventricular fibrillation episodes are terminated by the subject's device delivering a shock at the required energy level, or if one such episode is successfully terminated by the subject's device delivering a shock at a lower energy level. Up to 6 such episodes may be induced to test device efficacy.
Medtronic Cardiac Rhythm and Heart Failure
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04060680
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Scottsdale, Arizona, United States
View Trial DetailsNCT03608670
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Brisbane, Australia
View Trial DetailsNCT07258628
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07385040
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Karachi, Sindh, Pakistan
View Trial Details